INVENTIVA
Last · Paris€2.78+0.115 (+4.32%)live · yahoo · 53m ago
Vol 120.6K ≈ 335.3K
MA10MA20MA50
Market cap€656.7M236.2M sh
P/E · TTM-5.1fwd -4.7 · eps -0.54 · loss
Beta1.00vs S&P 500
Div yield0.00%annual · TTM
52w range
€2.57€6.20
Volume120.6Ksession
Issuer
Legal nameINVENTIVA
HQEurope (EU)
ListingEU IVA
ISINFR0013233012
SectorHealthcare
IndustryBiotechnology & Medical Research
CurrencyEUR
Entity registrylei:969500I9Y690B3FZW590
CIK0001756594
Websitewww.inventivapharma.com
Employees73
AddressInventiva SA 50, rue de Dijon 21121, Daix +33 3 80 44 75 00
| Revenue | €17.5M |
|---|---|
| Operating income | €-102.7M |
| Net income | €-110.4M |
| Free cash flow | €-89.3M |
| Operating margin | -587.7% |
| Net margin | -631.8% |
| Period | 2023 |
Loading chart…
OpenFilings analyst
Our analyst
ANNUAL · 2026-04-08
From latest ANNUAL · 2026-04-08
- Operating Cf Burn
- Net Margin Sharply Negative
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -7899.6%
Earnings transcripts
- Motley Fool
Inventiva (IVA) Q2 2026 Earnings Call Transcript
Inventiva S.A.
- Issuer webcast
Presentation — 2025 Full-Year Results
INVENTIVA
- Issuer webcast
General meeting replay
INVENTIVA
- Issuer webcast
General meeting replay
INVENTIVA
- Issuer webcast
General meeting replay
INVENTIVA
- Issuer webcast
Press Release — Inventiva’s 2022 First-Half Financial Results Presentation
INVENTIVA
Press & signals
- GlobeNewswire
Inventiva to Present Multiple Abstracts at Paris MASH 2026
- GlobeNewswire
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
- GlobeNewswire
Inventiva Appoints Chris Benecchi as Chief Operating Officer
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags
Showing 5 of 965 filings